Promoter collection, Human POU5F1 promoter
Alternative name | U3040-6 |
---|---|
Clone info. | PCR amplified human POU5F1 promoter sequence was inserted into a firefly luciferase vector. Cloned fragment: 31172142 to 31170650(NC_000006.12); relatively -1460 to +33, where +1 corresponds to 1 nt of NM_002701.6. |
Comment | PCR cloning, forward primer: ATTCTGTGTGAGGGGATTGG; reverse primer: CTGGTGAAATGAGGGCTTG. Known differences (at least): substitutions with NC_000006.12, G to A at 31,171,784nt, C to T at 31,171,713nt, T to C at 31,171,675nt, G to A at 31,170,930nt and C to T at 31,170,695nt. Entire sequence of promoter region has not been confirmed. |
Vector backbone | pGL4.10 [Luc2] (Plasmid) |
Selectable markers | Amp^r |
Gene/insert name | Human POU class 5 homeobox 1 genomic DNA |
Depositor|Developer | DNA Bank, | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation. |
必要書類 | 提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 謝辞の表明を必要とする。 MTAに書く付加的使用条件: 本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。 |
Catalog # | Resource name | Shipping form | Fee (non-profit org.) |
---|---|---|---|
RDB07912 | pGL4-phPOU5F1 | DNA solution |
Materials & Methods section:
The pGL4-phPOU5F1 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07912). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB07912_A1Ebp1-3.pdf |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: pGL4ins_F () Region: pause site,insert5' Sequence file: RDB07912_A1Eba.seq |
---|
>07912_07912_A9IdF_pGL4ins_F_B05_02_ABI08.ab1 1 NNNNNNNNNN NNNNNNNNCN NGNNNNNNNA GGCTGTCCCC AGTGCAAGTG CAGGTGCCAG 61 AACATTTCTC TGGCCTAACT GGCCGGTACC TGAGCTCGCT AGCCTCGAGG ATATTCTGTG 121 TGAGGGGATT GGGACTGGGG GGTTGGGGAG CAGGAAGCAG TCCCCAGGGG AGCCATCCAG 181 GCCCATTCAA GGGTTGAGCA CTTGTTTAGG GTTAGAGCTG CCCCCTCTGG GGACCGGGAT 241 TGTCCAGCCA AGGCCATTGT CCTGCCCCCT TCCCCCAGTC CCTCCCAGGC TTCTTTGAAC 301 CTGAAGTCAG ATATTTTTTC TCCACACCCC CCACCCCCTG GTTTTCCCCA CCCAGGGCCT 361 AGGGCTGGAG GCCTGGGCCA GGGAGGTGGG GGAGGGAGAA CGGGGCCTAC CGTGGTATTA 421 GATGTCTGAG TTTTGGTTGA GAGGGGAGCA AGGAACCTGA TGTGCAGGTT TCATAGTGGA 481 GGGGGCCCAA AGCGGGTGTC TTATCACTCT GTTTCAGCAA AGGTTGGGAA ACTGAGGCCC 541 AATCAGTCCA AAGTCTGGTC CCTTGAAGGG GAAGTAGGGG CCAACCCCTT AGTCTGTTAG 601 ATGAGGAGAG TCTGGAGTCT GATTCTGGAA GACGGAGGGG TGGGGGGATG GGGGGTGGNN // |
Primer: pGL4ins_R () Region: Luciferase5',insert3' Sequence file: RDB07912_A1Ebb.seq |
>07912_07912_A9IdF_pGL4ins_R_H02_08_ABI08.ab1 1 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN GCTGGGCCCT TCTTAATGTT TTTGGCNTCT 61 TCCNTGGTGG CTTTACCAAC AGTACCGGAT TGCCAAGCTT GGCCGCCGAG GCCAGATCTT 121 GATCTGGTGA AATGAGGGCT TGCGAAGGGA CTACTCAACC CCTCTCTCTC TCCCCAGTCC 181 CACCCACTAG CCTTGACCTC TGGCCCCGCC CCCTGGATGG GTGGAGGAGA GGGAGGTGGG 241 GGNNN // |
Primer: pGL4pA_R () Region: SV40p(A),Luciferase3' Sequence file: RDB07912_A1Ebc.seq |
>07912_07912_A9IdF_pGL4pA_R_D05_04_ABI08.ab1 1 NNNNNNNNNN NNNNNNNNNN NTNTCGNNTT NNCNNCNTTT GTAGAGGTTT TACTTGCTTT 61 AAAAAACCTC CCACACCTCC CCCTGAACCT GAAACATAAA ATGAATGCAA TTGTTGTTGT 121 TAACTTGTTT ATTGCAGCTT ATAATGGTTA CAAATAAAGC AATAGCATCA CAAATTTCAC 181 AAATAAAGCA TTTTTTTCAC TGCATTCTAG TTGTGGTTTG TCCAAACTCA TCAATGTATC 241 TTATCATGTC TGCTCGAAGC GGCCGGCCGC CCCGACTCTA GAATTATTAC ACGGCGATCT 301 TGCCGCCCTT CTTGGCCTTA ATGAGAATCT CGCGGATCTT GCGGGCGTCC AACTTGCCGG 361 TCAGTCCTTT AGGCACCTCG TCCACGAACA CAACACCACC GCGCAGCTTC TTGGCGGTTG 421 TAACCTGGCT GGCCACATAG TCCACGATCT CCTTCTCGGT CATGGTTTTA CCGTGTTCCA 481 GCACGACGAC TGCGGCGGGC AGCTCGCCGG CATCGTCGTC GGGCAGGCCG GCGACCCCGG 541 CGTCGAAGAT GTTGGGGTGT TGCAGCAGGA TGCTCTCCAG TTCGGCTGGG GCTACCTGGT 601 AGCCCTTGTA TTTGATCAGG CTCTTCAGCC GGTCCACGAT GAAGAAGTGC TCGTCCTCGT 661 CCCAGTAGGC GATGTCGCCG CTGTGCAGCC AGCCGTCCTT GTCGATGAGA GCGTTTGTAG 721 CCTCGGGGTT GTTAACGTAG CCGCTCATGA TCATGGGGCC ACGGACGCAC AGCTCGCCGC 781 GCTGGTTCAC ACCCAGTGTC TTACCGGTGT CCAAGTCCAC CACCTTANCC TCNAANANNG 841 GCACCACCTT GCCNACTGCG CCAGGCTNGT CGNCCCCTTC NGGGGGNNAT CANAANNGGC 901 GCNNGNTGTT TCTGNCNNNN CGTANNCCCT NGNNGNATGC CNNNNNNGTG GNANNCGTTT 961 NGNCNNCNNN CNNCANCNTA NNNNCNTNNN NNNNNNN // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content